AAAP Research Awards will be presented, and resident and medical student travel stipend recipients will be recognized during the awards ceremony. The annual all-member business meeting will follow the awards ceremony.

This session will provide an opportunity for members to get involved in considering how issues of conflict of interest and other ethical concerns should be dealt with in regard to AAAP events and programs. This year’s session will be a debate moderated by Mark L. Willenbring, M.D. The topic of discussion will be on how pharmaceutical companies distort scientific research and the presentation of scientific findings to professionals. Steven Miles, M.D., Professor of Medicine and Professor of Bioethics, University of Minnesota School of Medicine, Minneapolis, MN and Jeff Stier, Esq., Associate Director, American Council on Science and Health, New York, NY will take part in this debate. We invite you to join us at this town hall style forum!

Poster sessions are a way to share clinical, educational, and basic research information with colleagues. Posters will be displayed in the Exhibit Hall area. Papers on various substance abuse and mental health topics will be presented at the meeting. A complete listing of titles and faculty will be available at www.aaap.org.

BACK TO TOP

Workshop sessions are designed to be interactive and informal. They provide an opportunity to examine topics in depth, and they provide time for audience discussion and question and answer sessions. A complete listing of titles and faculty will be available at www.aaap.org.

Our Exhibit Hall will feature book publishers, treatment centers, government agencies, pharmaceutical companies, and behavioral healthcare systems.

This luncheon is a unique opportunity to have small group discussions with experts in the field.

The annual meeting mentor program will match senior colleagues with new members, residents and medical students. Scheduled activities include the Breakfast for Trainees, an opportunity for residents and medical students to meet with senior colleagues in the field of addiction psychiatry, and the New Member Orientation, an opportunity for new or prospective members to learn about AAAP. If you are interested in serving as a mentor or having a mentor at the Annual Meeting, please indicate this on your registration form.

Immediately following the last session on Sunday, there will be a prize drawing for all attendees present. Prizes will include a

variety of exciting items including free meeting registration for 2009 and luxury hotel accommodations.

Mark L. Willenbring, MD, Symposium Chair

Participants: Howard B. Moss, MD; Deborah A. Dawson, PhD; and Bridget F. Grant, PhD

The National Epidemiological Study on Alcohol and Related Conditions (NESARC) provides interview data on over 43,000 people in the US. Unique among such studies, the same sample has now been studied in two waves, three years apart, thus allowing prospective as well as cross-sectional data. The picture of risk drinking and alcohol use disorders thus provided is changing our understanding of the extent, nature, course and correlates of heavy drinking and alcohol use disorders. This symposium provides some of the most prominent examples. Dr. Willenbring will present a brief overview of the NESARC. Dr. Grant will present data on the incidence of new cases of mood, anxiety and substance use disorders over a three year period. Dr. Dawson will discuss determinants and patterns of remission, recovery and relapse. Dr. Moss will present his new typology of alcohol dependence based on latent trait analysis, and will also present data on the course over three years of each subtype.

Frances R. Levin, MD, Symposium Chair

Participants: Wim VandenBrink, MD; Christian Krappel, MD; Marc Auriacombe, MD; & Gabriele Fischer, MD

This symposium will focus on treatment strategies that are currently being implemented in several European countries and the impact that these approaches have had on substance use outcome. Dr. Wim van den Brink, Professor at the Academic Medical Center of University of Amsterdam, will be speaking on heroin-assisted treatment for chronic, treatment refractory methadone maintenance patients. Further, Dr. Christian Krappel from the JellinekMentrum Amsterdam will discuss the "Dutch experience" in the decriminalization of cannabis and the social/medical consequences of this policy. Dr. Marc Auriacombe, a Professor at the Victor Segalen University of Bordeaux, will be speaking about the French experience in implementing buprenorphine. Unlike the U.S., all medical doctors in France have been allowed to prescribe buprenorphine without any special education or licensing since 1996 and the implications of this policy will be discussed. Finally, Dr. Gabriele Fischer, Professor at the Medical University of Vienna will be describing her novel approaches in treating pregnant substance abusers. Together, this panel will discuss their clinical

experiences and how generalizable their findings might be to other countries, including the United States.

Susan Stine, MD, Symposium Chair

Participants: Carl Christensen, MD, PhD; Peter R. Martin, MD; Karol Kaltenbach, PhD; Sarah Heil, PhD; and Hendree Jones, PhD

The management of opioid dependence during pregnancy presents multiple challenges. In addition to the challenges of managing opioid pharmacotherapy during pregnancy there are also complex medical and obstetric issues, psychosocial issues, including attachment and parenting disorders, co-occurring smoking and other Axis I psychiatric disorders. These associated treatment needs also present medication concerns and ethical questions. The speakers in this symposium are drawn from investigators participating in the Maternal Opioid Treatment: Human Experimental Research (MOTHER) Project. The MOTHER study is a multi-site collaborative randomized clinical trial (RCT) conducted by eight collaborating sites in order to address clinical issues in this special population. This double-blind, double-dummy, RCT compares methadone and buprenorphine on a number of maternal and neonatal outcomes including the primary outcomes pertaining to the neonatal abstinence syndrome (NAS) and physical birth parameters of neonates. This symposium will include emerging data from the ongoing blinded study as well as literature reviews and additional research data gathered by these investigators. This symposium will first provide an overview of clinical treatment issues in this population from an obstetrical and addiction medicine perspective (Dr. Christensen). Parenting and attachment disorders in pregnant-opioid dependent patients will then be addressed (Dr. Kaltenbach) followed by a consideration of smoking and opioid dependence issues (Dr. Heil). The audience will also be provided with the most recent information on how to manage and effectively treat this patient population with medication, covering such topics as treating patients who present to treatment misusing prescription opioids, post-partum pain management and breastfeeding (Dr. Jones). The maternal and perinatal outcomes in infants exposed to opioid agonist, partial agonist or antagonist medication options will be summarized and will include a discussion of the implications for future research. Finally, Dr. Martin will discuss the ethical issues of prescribing opioid and other psychiatric medications to perinatal patients from the perspective of assessing risk and benefits of the various approaches available to the psychiatrist for management of this complex patient population.

Wilson M. Compton, MD, MPE, Symposium Chair

Participants: Faye Taxman, PhD; Roger Peters, PhD; and Robert Schwartz, MD

An estimated 6.7 million people are involved with some aspect of the criminal justice system with nearly 2.1 million in prison or jail and 4.8 million participating in community-based supervision. Among individuals incarcerated in state and federal prisons, 69% were involved in drug or alcohol related offenses, and 56% reported using illicit drugs in the month prior to committing the offense for which they were incarcerated. In addition, a recent survey found that within jails, 52% of the women and 44% of the men met DSM criteria for alcohol and/or drug dependence. Further, epidemiological studies have found high rates of mental health and co-occurring mental health and drug abuse disorders among individuals involved in the criminal justice system. A survey of individuals entering the Washington State prison system found that 84% of the men met DSM-IIIR criteria for Axis I or Axis II mental health disorders and substance use disorders. Finally, those involved in the criminal justice system are far more likely than the general public to have infectious diseases including HIV, AIDS, hepatitis C, and tuberculosis. This symposium will examine the current state of scientific knowledge and present findings from studies seeking to develop interventions and services to effectively address drug abuse, mental health disorders, and HIV among this population.

Michael M. Scimeca, MD, Chair, Moderator

Presenter: Abigail Schein, MD

Clinicians: Marc Galanter, MD; and Himanshu Upadhyaya, MD

How do addiction psychiatrists go about their clinical work: evaluating, considering, talking, suggesting, prescribing, consulting and more? This Case Conference is an opportunity to hear from two highly-respected clinicians about their work in the field. A case will be presented, and the clinicians will offer their comments on how each uniquely approaches treatment. Conference attendees will then be able to participate directly through questions, comments and their own case vignettes.

Mark L. Willenbring, MD, Chair

Presenter: Steven Miles, MD, Professor of Medicine and Bioethics, University of MInnesota School of Medicine, Minneapolis, MN

End-of-life care has evolved considerably in the past twenty years. Steven Miles, MD, is a geriatrician and bioethicist who has played a prominent role in defining ethical approaches to the many dilemmas faced by physicians, patients, and families, including a landmark court case involving obligations of physicians and hospitals when there is no hope of recovery. In the presentation, he will address controversial issues such as autonomy, pain control, sedation, nutrition and hydration, extubation and futility.